^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/14/2020
Excerpt:
The NCCN Panel recommends that this pembrolizumab treatment option be extended to patients with esophageal adenocarcinomas with PD-L1 expression levels by CPS of ≥1.
Excerpt:
Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
Source:
Title:
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Excerpt:
...PD-L1 expression status in tissue samples collected at baseline before receiving any prior systemic anticancer therapy are of highest interest....
Trial ID:
Source:
Title:
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
Published date:
06/16/2023
Excerpt:
6/29 (21%; 95% CI: 0.08-0.40) achieved ypCR with TRS 0 in resected patients. 26/29 (90%; 95% CI: 0.73-0.98) had ypRR with TRS ≤2. Twenty-six patients finished adjuvant therapy with a median 36.3-month follow-up...Preoperative ICI + chemotherapy enhanced immune responses significantly with increasing expression of PD-L1 (CPS ≥10, p = 0.0078) and CD8 (>5%, p = 0.0059)...The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long-time survival benefits.
Secondary therapy:
mFOLFOX6
DOI:
10.1002/cam4.6263
Trial ID:
